MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico

• 主要な著者: Aurelio Cruz-Valdez (著者), Gabriel Valdez-Zapata (著者), Sanjay S. Patel (著者), Flavia V. Castelli (著者), Marcia G. Garcia (著者), Wim T. Jansen (著者), Ashwani Kumar Arora (著者), Esther Heijnen (著者)
• フォーマット: 図書
• 出版事項: Taylor & Francis Group, 2018-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

The poor immune response elicited by trivalent influenza vaccines (TIVs) in children can be enhanced by the addition of adjuvants. This observer-blind, randomized Phase III trial assessed the immunogenicity and safety of the MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV) and a non-adjuvan...